Rare Pancreatic Tumors

Amitkumar Choudhari, Pooja Kembhavi, Mukta Ramadwar, Aparna Katdare, Vasundhara Smriti, Akshay D. Baheti

Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
Department of Radiodiagnosis, Homi Bhabha National University, Mumbai, Maharashtra, India
Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
Department of Pathology, Homi Bhabha National University, Mumbai, Maharashtra, India

Address for correspondence Akshay D. Baheti, MD, Department of Radiodiagnosis, Tata Memorial Hospital, Ernest Borges Marg Parel Mumbai 400012, India (e-mail: akshybaheti@gmail.com).

Abstract

Pancreatic ductal adenocarcinoma, neuroendocrine tumor, and cystic pancreatic neoplasms are the common pancreatic tumors most radiologists are familiar with. In this article we review the clinical presentation, pathophysiology, and radiology of rare pancreatic neoplasms. While the imaging features are usually nonspecific and diagnosis is based on pathology, the radiology along with patient demographics, history, and laboratory parameters can often help indicate the diagnosis of an uncommon pancreatic neoplasm and guide appropriate management in these cases.

Keywords

► pancreatic cancer
► uncommon
► pancreatoblastoma
► acinar cell
► lymphoma

Introduction

Pancreatic tumors of various histological subtypes can be encountered in clinical practice, most common being pancreatic ductal adenocarcinoma (PDAC), which constitutes 85% of all pancreatic neoplasms. Histologically pancreatic neoplasms can be of epithelial and nonepithelial origin (►Table 1). The less common epithelial neoplasms will be discussed in this review, include acinar cell neoplasm, adenosquamous carcinoma, and pancreatoblastoma. Nonepithelial neoplasms can arise from intrapancreatic or peripancreatic mesenchymal, hematopoietic, or neural elements. These account for only 1 to 2% of all pancreatic neoplasms, and will also be discussed.

Epithelial Neoplasms

Pancreatic Acinar Cell Tumor

Acinar cell carcinoma (ACC) comprises only 1% of all pancreatic neoplasms. The neoplasm is usually encountered in the fifth to seventh decade of life, with a stark male preponderance. It is a neoplasm of the exocrine pancreas, but can occasionally also have an endocrine component. The tumor cells can secrete pancreatic enzymes, especially lipase. Resulting hyperlipasemia may rarely lead to extraabdominal manifestations like ectopic subcutaneous fat necrosis and polyarthrits (lipase hypersecretion syndrome).

These tumors are hypoenhancing compared with the pancreas and are frequently associated with cystic or necrotic areas as well as calcifications, also unlike PDAC. Due to their lower propensity for vascular, lymph node, and adjacent soft tissue invasion, gross total resection can more often be achieved.

Adenosquamous Carcinoma of the Pancreas

Adenosquamous carcinoma of the pancreas is another rare neoplasm of the pancreas, constituting 1 to 4% of adenocarcinomas. It has a slight male preponderance and is found in the seventh decade of life. The diagnosis is based on the presence of ≥30% squamous component within the lesion on pathology. Signs and symptoms like weight loss, anorexia, jaundice, and abdominal and back pain are similar to PDAC.
## Table 1  World Health Organization classification of pancreatic tumors

<table>
<thead>
<tr>
<th>Epithelial tumors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benign</strong></td>
<td></td>
</tr>
<tr>
<td>Acinar cell cystadenoma</td>
<td></td>
</tr>
<tr>
<td>Serous cystadenoma</td>
<td></td>
</tr>
<tr>
<td><strong>Premalignant lesions</strong></td>
<td></td>
</tr>
<tr>
<td>Pancreatic intraepithelial neoplasia, grade 3 (PanIN-3)</td>
<td></td>
</tr>
<tr>
<td>Intraductal papillary mucinous neoplasm (IPMN) with low- or intermediate-grade dysplasia</td>
<td></td>
</tr>
<tr>
<td>Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia</td>
<td></td>
</tr>
<tr>
<td>Intraductal tubulopapillary neoplasm (ITPN)</td>
<td></td>
</tr>
<tr>
<td>Mucinous cystic neoplasm (MCN) with low- or intermediate-grade dysplasia</td>
<td></td>
</tr>
<tr>
<td>Mucinous cystic neoplasm (MCN) with high-grade dysplasia</td>
<td></td>
</tr>
<tr>
<td><strong>Malignant lesions</strong></td>
<td></td>
</tr>
<tr>
<td>Ductal adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mucinous adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Hepatoid carcinoma</td>
<td></td>
</tr>
<tr>
<td>Medullary carcinoma</td>
<td></td>
</tr>
<tr>
<td>Signet ring cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>Undifferentiated carcinoma</td>
<td></td>
</tr>
<tr>
<td>Undifferentiated carcinoma with osteoclast-like cells</td>
<td></td>
</tr>
<tr>
<td>Acinar cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>Acinar cell cystadenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mixed acinar ductal carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mixed acinar neuroendocrine carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mixed acinar neuroendocrine ductal carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mixed ductal neuroendocrine carcinoma</td>
<td></td>
</tr>
<tr>
<td>Mucinous cystic neoplasm (MCN) with an associated invasive carcinoma</td>
<td></td>
</tr>
<tr>
<td>Pancreatoblastoma</td>
<td></td>
</tr>
<tr>
<td>Serous cystadenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Solid pseudopapillary neoplasm</td>
<td></td>
</tr>
<tr>
<td><strong>Neoplasms of the neuroendocrine pancreas</strong></td>
<td></td>
</tr>
<tr>
<td>Nonfunctioning (nonsyndromic) neuroendocrine tumors</td>
<td></td>
</tr>
<tr>
<td>Pancreatic neuroendocrine microadenoma</td>
<td></td>
</tr>
<tr>
<td>Nonfunctioning pancreatic neuroendocrine tumor</td>
<td></td>
</tr>
<tr>
<td>Insulinoma</td>
<td></td>
</tr>
<tr>
<td>Glucagonoma</td>
<td></td>
</tr>
<tr>
<td>Somatostatinoma</td>
<td></td>
</tr>
<tr>
<td>Gastrinoma</td>
<td></td>
</tr>
<tr>
<td>VIPoma</td>
<td></td>
</tr>
<tr>
<td>Serotonin-producing tumors with and without carcinoid syndrome</td>
<td></td>
</tr>
<tr>
<td>Serotonin-producing tumor</td>
<td></td>
</tr>
<tr>
<td>ACTH-producing tumor with Cushing syndrome</td>
<td></td>
</tr>
<tr>
<td>Pancreatic neuroendocrine carcinoma (poorly differentiated neuroendocrine neoplasm)</td>
<td></td>
</tr>
<tr>
<td>Neuroendocrine carcinoma (poorly differentiated neuroendocrine neoplasm)</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
However, the prognosis is poorer compared with PDAC. On imaging, adenosquamous carcinomas are round-lobulated lesions associated with extensive necrosis. Tumor thrombosis of portal venous (PV) system can help to differentiate these lesions from PDAC; the latter tends to encase the vessels and cause occlusion of PV system due to bland thrombosis. The differential diagnosis also includes anaplastic/undifferentiated carcinoma, neuroendocrine carcinoma, and acinar cell carcinoma, among others.

### Pancreatoblastoma

Pancreatoblastoma is a rare primary neoplasm of the pancreas occurring in childhood. The tumor is usually seen in 1 to 8 years age group. Pancreatoblastoma arises from acini which resemble the tissue of fetal pancreas at 7 weeks gestation. Clinically, it presents as a large abdominal mass with pressure symptoms like pain, early satiety, obstructive jaundice, vomiting, and constipation. The tumor usually does not cause bowel or biliary obstruction despite its large size, since it has a soft, gelatinous consistency. The α fetoprotein levels can be elevated in 25 to 55% cases. Congenital pancreatoblastoma can be associated with Beckwith–Wiedemann syndrome, where the tumor can be cystic. Anatomically, the lesion can occur in any part of the pancreas or involve the entire organ.

Ultrasound usually demonstrates a heterogeneous complex cystic/necrotic mass with thick echogenic septa. On computed tomography (CT)/magnetic resonance imaging (MRI), the lesion presents as a well-defined or a partially circumscribed, lobulated mass with enhancing septa on
Rare Pancreatic Tumors

Choudhari et al.

Journal of Gastrointestinal and Abdominal Radiology ISGAR Vol. 3 No. 1/2020

CT\textsuperscript{12,13} (►Fig. 2). There is a propensity for adjacent soft tissue invasion, including involvement of the duodenum, adrenals, spleen, and even neurovascular infiltration. Calcifications can also be seen, and are usually rim-like or clustered if present.\textsuperscript{12} Metastases to liver, omentum, and peritoneum can occur. In large masses, it can often be difficult to ascertain whether the pancreas is the organ of origin or just secondarily involved. Differentials like neuroblastoma, Wilms tumor, or non-Hodgkin’s lymphoma (NHL) would need to be considered, and a biopsy may be necessary. Neuroblastoma can be differentiated MIBG positivity on nuclear imaging study, presence of urine catecholamines, and paraneoplastic syndromes like opsoclonus-myoclonus. Wilms tumor may be differentiated by its propensity for venous invasion, pulmonary metastasis, and renal origin. NHL can also present as a large retroperitoneal mass which may involve the pancreas. Lack of necrosis and calcification within the mass can help to differentiate NHL from other retroperitoneal masses in children. Surgery is the treatment of choice.\textsuperscript{12,13}

Hematolymphoid Tumors

Pancreatic involvement by hematolymphoid malignancies like lymphomas, leukemias, and plasmacytomas are rare but can occur.

Pancreatic Lymphoma

Pancreatic lymphoma can arise primarily in the pancreas or secondarily involve pancreas in the presence of systemic disease (►Figs. 3 and 4). Primary pancreatic lymphoma is an exceedingly rare neoplasm, representing only 0.1% of malignant lymphomas and 0.2% of primary pancreatic tumors.\textsuperscript{14} The Dawson criteria\textsuperscript{15} for diagnosis of primary pancreatic lymphoma include lymphoma arising as a mass within the pancreas and peripancreatic lymph nodes with no liver or spleen involvement, no superficial or mediastinal lymphadenopathy, and a normal leukocyte count. Patients can be asymptomatic or present with abdominal pain. B symptoms like fever, night sweats, and weight loss can also be encountered. Occasionally patients can also present with gastric outlet obstruction, or rarely, GI bleeding.\textsuperscript{16}

Fig. 2 (A, B) A 9-year-old boy presenting with an incidentally detected abdominal lump. Axial and coronal (CECT) images show a large heterogeneous predominantly solid mass arising from the tail of the pancreas and encasing and narrowing the splenic vein (arrows). It demonstrates a cystic/necrotic focus within (B). The possibility of a pancreatoblastoma was raised given the patient’s age and the imaging features. The patient underwent distal pancreaticosplenectomy, which confirmed the diagnosis. (C) Hematoxylin and eosin–stained section (10×) shows a cellular tumor composed of uniform tumor cells arranged in acini and cords. Nuclear pleomorphism and mitotic activity are not conspicuous. Findings are diagnostic of pancreatoblastoma.

Fig. 3 A 54-year-old man with abdominal pain and weight loss. Axial CECT images revealed a large infiltrative homogeneously enhancing lesion (arrow) in the body of the pancreas (A). There were multiple discrete homogeneous enlarged retroperitoneal and mesenteric nodes (arrowheads) present as well (B), consistent with the diagnosis of lymphoma with secondary pancreatic involvement. Biopsy revealed chronic lymphocytic lymphoma.
Pathologically, the diffuse large B cell lymphoma is more common. Other less common variants which may be encountered include follicular and marginal zone lymphoma. Diagnostic confirmation through percutaneous/endoscopic US-guided biopsy or surgical biopsy is important, because pancreatic lymphoma needs to be treated by chemotherapy, whereas pancreatic adenocarcinoma treatment warrants surgery with or without chemoradiation.

Although PPL can arise anywhere in the pancreas, the incidence is higher in the head of pancreas due to abundance of lymphoid tissue in the head. PPL is usually large at presentation. On ultrasonography (USG), pancreatic lymphoma appears as bulky homogeneous hypoechoic mass confined to the pancreas, without posterior acoustic enhancement. On cross-sectional imaging, PPL can be present as a focal well-defined soft tissue mass or a diffuse, ill-defined, infiltrative mass. CT will demonstrate a homogeneously hypoenhancing mass, without any calcification or necrosis in most cases ( Fig. 4 ). Ductal dilatation and vascular occlusion/invansion are absent just like lymphomas elsewhere in the body, despite the large tumor size. This finding is in stark contrast to imaging features of adenocarcinoma, which cause ductal dilatation even when much smaller in size. MRI offers no additional advantage over CT in characterizing the lesion. On FDG PET/CT, (fluorodeoxy glucose – positron emission tomography) pancreatic lymphoma is an avid tumor with various patterns of FDG uptake—focal nodular uptake (solitary or multifocal), segmental uptake, or diffuse uptake. PDAC can also demonstrate focal FDG uptake; however, lymphoma tends to be much more FDG avid with maximal standardized uptake values (SUVmax) reportedly ranging from 7.4 to 26.5, compared with pancreatic adenocarcinoma, which is relatively less FDG avid with SUVmax ranging from 2 to 12. There remains an overlap though, and biopsy is needed for diagnosis.

The main differential for PPL is PDAC, given its higher incidence. Imaging features like large size, homogeneous appearance, lack of ductal dilatation, absence of invasion/occlusion of the portal, superior mesenteric, or splenic vein despite encasement indicates PPL over PDAC. Infrarenal adenopathy, below the level of renal veins, is also suggestive of pancreatic lymphoma. Presence of a mass, which infiltrates intra-abdominal organs, crosses anatomic boundaries, and stretches vessels without encasement/thrombosis, is also more likely to represent pancreatic lymphoma. Autoimmune pancreatitis is another differential for smaller lesions.

**Plasmacytoma**

Pancreas is a rare site of extramedullary or solitary plasmacytoma, which occurs due to monoclonal proliferation of plasmocytes outside the marrow. Pancreatic involvement by plasmacytoma/multiple myeloma is exceedingly rare, accounting for less than 0.1% of pancreatic masses.

Pancreatic plasmacytoma tends to affect middle-aged men (median age, 55 years). These can be solitary, where head is the usual site, or multifocal. Plasmacytomas frequently secrete M-protein, which is detectable in serum or urine. Patients with pancreatic head plasmacytoma can present with obstructive jaundice, similar to PDAC. Plasmacytomas demonstrate immunoreactivity to CD38 and CD138 and κ or λ light chain restriction. On USG, the lesion is seen as hypoechoic mass associated with biliary dilatation. Plasmacytomas are usually hyp- and isoenhancing masses on CT and MRI but may demonstrate arterial phase hyperenhancement ( Fig. 5 ). They are hypointense on T2-weighted images.
due to their high cellularity and will show diffusion restriction, a clue to the diagnosis.\textsuperscript{19} They demonstrate intense FDG avidity on PET/CT (\textsuperscript{\textbullet} Fig. 5C).\textsuperscript{19}

The imaging differentials for a plasmacytoma would include primary pancreatic lymphoma, primitive neuroendocrine tumor, sarcoma, and metastasis. Biopsy remains essential for diagnosis.

**Mesenchymal Tumors**

Mesenchymal tumors, including both benign/less aggressive tumors and sarcomas, uncommonly involve the pancreas, and usually present as indeterminate heterogeneous masses which can be differentiated only on histopathology. We describe a few pancreatic mesenchymal tumors.

**Perivascular Epithelioid Cell Tumor**

Perivascular epithelioid cell tumors (PEComas) comprise a rare family of mesenchymal tumors found at various anatomical sites, sharing the distinctive perivascular epithelioid cells, which demonstrate characteristic immunophenotype and morphology. They are also known as “sugar tumors” due to the glycogen rich cytoplasm of the perivascular epithelioid cells.\textsuperscript{20,21} PEComas are frequently associated with germ-line mutations in the tuberous sclerosis complex genes.\textsuperscript{22} The neoplasm has a strong female preponderance. On imaging, PEComas present as large well-defined, encapsulated, and hypoenhancing masses.\textsuperscript{20} There are no characteristic imaging features to help differentiate them from other neoplasms.

**Solitary Fibrous Tumor**

Solitary fibrous tumors (SFTs) are rare mesenchymal tumors, constituting less than 1% of pancreatic neoplasms. Initially, thought to be an exclusively pleural neoplasm, it is now established that it can arise in any anatomical site in the body, extrapleural SFTs being more common.\textsuperscript{23} On pathology, SFTs are composed of whorled pattern of spindle cells and collagen, which comprises the fibrous variant, whereas the cellular form has a patternless or monotonous appearance. The fibrous form exhibits strong CD34 immunoreactivity compared with the cellular variant and is S100 negative. Malignant SFTs, however, lose CD34 immunoreactivity and overexpress S100, in addition to demonstrating cellular atypia, high mitotic activity, and higher frequency of necrotic and hemorrhagic areas.

Pancreatic SFTs, similar to other extrathoracic SFTs have a female predilection. Usually, these tumors can be encountered in the 41 to 78 years of age group, varying in size from 2 to 8 cm, but are generally large at presentation.\textsuperscript{24} They are slow-growing tumors, and the patients can present with abdominal distension, bowel obstruction, or constipation once the tumor becomes large in size. Obstructive jaundice is uncommon. Less than 5% of patients with SFTs, especially malignant tumor, may present with hypoglycemia due to secretion of insulin-like growth factor (Doerge–Potter syndrome). Other symptoms can include clubbing, hypertrophic osteoarthropathy, and arthralgia.\textsuperscript{24}

On imaging, pancreatic SFTs are seen as well-circumscribed hypervascular masses, with the cellular tumors demonstrating prominent arterial phase enhancement and both subtypes showing persistent progressive enhancement on the venous and delayed phases. Mixed pattern of enhancement with nonenhancing cystic/necrotic changes can be seen as well in large tumors. On catheter angiography, the lesion is hypervascular with arborizing vessels arising from a vascular stalk, along with dilated feeding arteries and early draining veins. Hence preoperative embolization may be useful in reducing intraoperative blood loss.\textsuperscript{25} Imaging differentials include nonfunctioning pancreatic neuroendocrine tumors, solid pseudopapillary neoplasm, and occasionally hypervascular metastasis; biopsy is needed for a definitive diagnosis. Surgery is the treatment of choice.

**Neurogenic Tumors**

**Neurofibroma**

Neurofibromas are neurogenic tumors composed of all components of the peripheral nerve, including Schwann cells, fibroblasts, perineural cells, and axons.\textsuperscript{1} Neurofibromas are associated with neurofibromatosis type 1 (von Recklinghausen disease), an autosomal dominant disorder predisposing to formation of plexiform neurofibromas. Pancreatic involvement can rarely occur by intraparenchymal growth of peripheral neurofibroma, which can result in abdominal pain and duct obstruction.\textsuperscript{25}

Neurofibromas are homogeneously hypointense and show mild contrast enhancement on CT scan. On MRI, neurofibromas are hypointense on T1 and heterogeneously hyperintense on T2-weighted images. Target appearance may be appreciated on T2-weighted images as central hypointensity with high peripheral T2 signal, corresponding to central well-organized tissue. Whorled appearance with T2 hypointense curvilinear areas may be seen, corresponding to bundles of collagen and Schwann cells, may also be encountered. Malignant transformation is rare and can be suggested by include rapid growth, necrosis, hemorrhage, calcification, loss of the “target sign” (due to loss of cellular organization), and invasion into adjacent structures with associated edema. Surgical excision, though challenging, is the standard treatment.

**Schwannoma**

Schwannomas are benign nerve sheath tumors, entirely composed of the myelin-producing neurilemma cells.\textsuperscript{26} Usually solitary, multiple schwannomas can be associated with type 2 neurofibromatosis. Schwannomas can be found at almost every location of the body including in extremities, head, neck, retroperitoneum, mediastinum, pelvis, and rectum. Visceral involvement is rare. These neoplasms are usually found in adults, without any gender predilection. Due to their slow growing nature, pancreatic Schwannomas are usually large at presentation with an average size of 9 cm (range: 2–20 cm).\textsuperscript{1} Clinically, patients can present with vague abdominal pain, although anorexia, back pain, vomiting, weight loss, and gastrointestinal bleeding.\textsuperscript{27} Histologically, schwannomas have two main features: highly cellular “Antoni A” areas and a sparsely cellular, myxoid, or
“Antoni B” component. Schwannomas exhibit strong S–100 immunoreactivity.27

On CT and MRI, pancreatic schwannomas reflect their architecture—the cellular Antoni A schwannomas are solid lesions with heterogeneous enhancement, whereas the Antoni B–predominant schwannomas are homogeneous cystic or multiseptated masses.2 Two-thirds of pancreatic schwannomas undergo degenerative changes such as cyst formation, necrosis, calcification, and hemorrhage, and these changes can mimic pancreatic cystic tumors including cystic neuroendocrine tumors,26 needing histopathological confirmation. At MRI, pancreatic schwannomas are T1 hypointense and T2 hyperintense. On contrast-enhanced study, Antoni A schwannomas reveal intense contrast enhancement, whereas Antoni B schwannomas show little enhancement, with nonenhancing, T2-hyperintense cystic areas.28

Conservative surgery like enucleation, where achievable, can be curative, due to benign nature of the neoplasm. A more radical approach may be warranted when rapid growth, infiltration of adjacent structures, and prominent necrotic and hemorrhagic changes within the tumor are encountered, suggesting malignant transformation.28

**Hemangioma**

Pancreatic hemangiomas are exceedingly rare neoplasms, which may be encountered in the pediatric age group and to a lesser extent in adults. Usually detected in infancy, the lesion can evolve through a proliferative phase in infancy to an involuting phase of variable duration lasting up to 12 years of age, finally reducing to a fibrofatty residuum in adulthood.29 Multiphase contrast-enhanced CT scan/MRI can reveal typical irregular enhancement with centripetal fill-in in the infantile hemangioma. Adult hemangiomas, however, do not reveal arterial enhancement, unlike hepatic hemangioma, with or without delayed enhancement suggesting a cystic neoplasm. Multiphase CT cannot exclude pancreatic hemangioma.30,31 Low T1 signal and high T2 signal may be considered suggestive of hemangioma in an enhancing lesion.32 Diagnosis is usually confirmed at histopathology, with the lesion expressing CD31 and CD34 immunoreactivity.31 A more conservative surgical approach can be considered in such neoplasm instead of extensive procedure like Whipple’s surgery in patients who are clinically symptomatic or present with complications like hemorrhage, mass effect like obstructive jaundice.

**Mesenchymal Sarcomas**

Sarcomas of the pancreas are exceedingly rare, amounting to 0.1% of pancreatic neoplasms.2 Except for primitive neuroectodermal tumors and rhabdomyosarcomas, which are encountered in children and young adults, most pancreatic sarcomas predominantly affect the elderly, with a median age of 65 years at diagnosis.2 Clinically, most patients present with vague abdominal pain and a large indeterminate mass. The mass is usually large at presentation, and to differentiate a primary retroperitoneal mass secondarily involving the pancreas from a primary pancreatic mass. A mass epicentered in the pancreas is assumed to be pancreatic/peri-pancreatic in origin. We discuss some “common” sarcomas. Histopathology remains essential for diagnosis.

**Leiomyosarcoma**

Leiomyosarcoma is the most common type of pancreatic sarcoma, thought to arise from the smooth muscles of the pancreatic duct or small intrapancreatic blood vessels. Pancreas can also be secondarily involved by leiomyosarcoma originating in the retroperitoneum, mimicking a primary pancreatic neoplasm.

On imaging, these tumors are usually large and heterogeneous, with peripheral hypervascularity and central areas of cystic degeneration/necrosis (Fig. 6). On MRI, the lesions are hypointense to the pancreas on T1-weighted images and hyperintense on T2-weighted images. Usually, these tumors present with distant metastasis, which can be detected with high sensitivity using 18F-FDG PET/CT.2

**Extraskeletal Ewing’s Sarcoma/Primitive Neuroectodermal Tumor**

Extraskeletal Ewing’s sarcoma (EES) and primitive neuroectodermal tumors are rare aggressive tumors arising from ectopic neural and neuroectodermal tissue and can occur anywhere in the body. They occur almost exclusively in children and young adults.3 Because of their similar morphology, immunohistochemistry, and cytogenetic alterations (t[11; 22]), these tumors are documented together with the Ewing’s sarcoma family.

These neoplasms present as large solid masses with cystic degeneration and necrosis, similar to other sarcomas. Peripheral hyperenhancement may be seen.33 They are FDG avid on PET/CT, a useful modality for detection of the primary tumor, postresection recurrence, and metastases.3

**Undifferentiated Pleomorphic Sarcoma**

Undifferentiated pleomorphic sarcoma is a common retroperitoneal sarcoma, more common in the elderly, and can rarely arise from the pancreas. On imaging, the tumor may present as large, heterogeneous mass with necrotic components. Calcification may be present.3 The tumor is FDG avid on PET/CT. It will remain an indeterminate pancreatic malignancy on imaging, and histopathology is necessary for diagnosis.

**Metastasis**

Pancreatic metastases account for only 2% of pancreatic neoplasms. Most common tumors metastasizing to the pancreas include renal, lung, breast, and melanoma.33 Renal cell carcinoma and melanoma metastases are often hypervascular. It is unlikely for pancreatic metastasis to present before the detection of primary neoplasm. Metastases, particularly renal cell carcinoma metastases, can occur even several years following the resection of the primary, with recurrences being reported even 12 to 32 years after surgery (Fig. 7).33

Patients are often asymptomatic, with the pancreatic metastases being an “incidental” finding on surveillance.
study. Nonspecific symptoms like abdominal pain, gastrointestinal bleeding, and weight loss can be present. Occasionally, a pancreatic head metastasis can cause biliary obstruction and result in jaundice. Pancreatic ductal obstruction can lead to upstream parenchymal atrophy. Usually patients with pancreatic metastases would have concurrent widespread disease. In patients with isolated pancreatic involvement, surgical resection may offer survival benefit, especially when the metastasis is detected after a prolonged disease-free interval, suggestive of biological pattern of slow growth.

On cross-sectional imaging, there are usually three patterns of pancreatic involvement—solitary mass, multifocal lesions, and a diffusely infiltrative lesion. Hyperenhancing pancreatic metastases include RCC and melanoma metastases, while lung, colonic, and gastric secondaries are usually hypoenhancing on contrast enhanced CT/MRI (►Fig. 8). A commonly encountered feature among hypervascular metastases is that smaller tumors enhance homogenously and larger (>1.5 cm) lesions show peripheral enhancement due to central hypoperfusion/necrosis. Hypervascular metastases may show intense early enhancement on arterial phase, followed by washout on portal and delayed phase images.

Differentials of hypervascular metastases include pancreatic neuroendocrine tumor and intrapancreatic accessory spleen. A relative percentage washout value (RPW = (A_p - A_a) / A_a × 100) where A_p and A_a are attenuation values of the pancreatic mass on 25 second arterial and 70 second portal contrast-material–enhanced CT scan) of 19% (RCC median: 27.1; NET median: 3.9) can be used to differentiate between RCC...
metastasis to the pancreas from pancreatic neuroendocrine tumor, in post nephrectomy surveillance patients.\cite{34} Accessory intrapancreatic spleen has attenuation similar to the spleen on contrast enhanced as well as unenhanced studies, including all MRI sequences. Definitive diagnosis can be established with scintigraphy using either technetium Tc 99m–labeled damaged red blood cell or technetium Tc 99m–sulfur colloid. Alternatively, the diagnosis can also be confirmed on MRI using reticuloendothelial system specific contrast agent (superparamagnetic iron oxide)–enhanced study, where the lesion as well as spleen will show drop in signal intensity on T2 and T2* sequences.\cite{45} Solitary hypoenhancing metastasis can resemble pancreatic adenocarcinoma. A large pancreatic head mass without biliary/pancreatic ductal dilatation/posterior fat infiltration should raise a suspicion of nonpancreatic nature of the neoplasm. Metastases also tend to have features of the primary neoplasm.\cite{34}

**Differential Diagnosis and Take-Home Points**
PDAC and neuroendocrine tumors are the most common solid pancreatic neoplasms, which need to be considered first in any case of a pancreatic mass. Any unusual features of presentation such as large size, heterogeneity with necrosis or hemorrhage, lack of ductal dilatation or jaundice, lack of parenchymal atrophy, or unusual age, should raise suspicion of a different etiology.\cite{3} Correlating the imaging findings with patient demographics, history, clinical symptoms, and laboratory parameters can help narrow the differentials. The pattern of enhancement, that is, hypoenhancing versus hypoenhancing/hypervascular lesions is often helpful.\cite{44} Hypoenhancing tumors resemble PDAC and include adenocarcinoma, ACC, and nonepithelial neoplasms such as lymphoma and some metastases. Hypenhernaching masses can resemble pancreatic neuroendocrine tumors and include hypervascular metastases, and (rarely) solitary fibrous tumors.\cite{46} Having said that, image guided biopsy remains the mainstay for diagnosis, and attempting to give a definitive diagnosis based on imaging alone should be avoided in most cases (\textit{► Table} 2).

**Table 2**  Summary of clinicoradiological features of rare pancreatic neoplasms

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Age</th>
<th>Gender</th>
<th>Clinical features</th>
<th>Location</th>
<th>Imaging findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreatic acinar cell tumor</td>
<td>5th–7th decade</td>
<td>M&gt;&gt;&gt;F</td>
<td>Lipase hypersecretion syndrome (subcutaneous fat necrosis, polyarthritis)</td>
<td>Any site in the pancreas</td>
<td>Hypoenhancing similar to PDAC with frequent cystic/necrotic component and calcifications</td>
</tr>
<tr>
<td>Pancreatoblastoma</td>
<td>1st decade</td>
<td>M&gt;&gt;F</td>
<td>Large abdominal mass with pressure symptoms</td>
<td>Any part</td>
<td>Well-defined to partially circumscribed, lobulated mass Can be cystic</td>
</tr>
<tr>
<td>Perivascular epithelioid cell tumor</td>
<td>F&gt;&gt;&gt;M</td>
<td>Frequently associated with tuberous sclerosis</td>
<td>Any part</td>
<td>Well-defined, encapsulated, and hypoenhancing pancreatic mass</td>
<td></td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td>7th decade</td>
<td>M&gt;F</td>
<td>Weight loss, anorexia, jaundice, abdominal and back pain are similar to PDAC</td>
<td>Head</td>
<td>Round-lobulated lesions associated with extensive necrosis Tumor thrombus in portal vein</td>
</tr>
<tr>
<td>Solitary fibrous tumor (SFT)</td>
<td>5th–8th decade</td>
<td>F&gt;&gt;M</td>
<td>Abdominal distension, bowel obstruction, or constipation Hypoglycemia (Dooge–Potter syndrome) Clubbing, hypertrophic osteoarthropathy, and arthralgia</td>
<td>Head</td>
<td>Large hypervascular mass with persistent progressive enhancement on multiphase studies</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>7th decade</td>
<td>M&gt;&gt;F</td>
<td>Asymptomatic or abdominal pain B symptoms like fever, night sweats, and weight loss</td>
<td>Head &gt;&gt;body/tail</td>
<td>Focal lesion or diffuse, ill-defined, infiltrative mass No ductal dilatation and vascular occlusion/invasion, even if large Associated large adenopathy</td>
</tr>
<tr>
<td>Sarcomas</td>
<td>Usually older age group</td>
<td></td>
<td>Abdominal distention or pain</td>
<td>Any</td>
<td>Large, heterogeneous, masses without a distinguishing imaging feature</td>
</tr>
</tbody>
</table>

Abbreviations: M, male; F, female; PDAC, pancreatic ductal adenocarcinoma.
Conflict of Interest
None declared.

Acknowledgment
The authors wish to acknowledge Dr. Atul Shinagare, Assistant Professor, Department of Radiology, Dana Farber Cancer Institute, Harvard Medical School, for contributing one of the figures for the manuscript.

References
22 Hornick JL, Fletcher CDM. PEComa: what do we know so far? Histopathology 2006;48(1):75–82